Literature DB >> 18303245

Abnormal localization and accumulation of FLT3-ITD, a mutant receptor tyrosine kinase involved in leukemogenesis.

Sina Koch1, Angela Jacobi, Martin Ryser, Gerhard Ehninger, Christian Thiede.   

Abstract

Aberrant subcellular localization of mutant transmembrane receptors is increasingly acknowledged as a possible mechanism for an altered signaling quality leading to transformation. There is evidence that mutated receptor tyrosine kinases of subclass III, for example the platelet-derived growth factor receptor (PDGFR) and KIT-protein, are aberrantly localized in human cancers. In order to further analyze this phenomenon, we investigated the localization of FLT3, a subclass III receptor tyrosine kinase frequently mutated in leukemia. By immunofluorescence staining and confocal laser scanning microscopy we found that in retrovirally transduced COS7 cells, wild type FLT3 receptor protein is localized primarily at the cell surface. In contrast, a mutant FLT3 receptor protein with an internal tandem duplication (ITD) accumulates in a perinuclear region and is not detectable at the plasma membrane. Surprisingly, and in contrast to previously published data, intracellular FLT3-ITD accumulation could neither be detected in the endoplasmic reticulum (ER) nor in the Golgi apparatus. Furthermore, transient overexpression per se leads to accumulation of wild type FLT3 receptor protein in the ER in addition to surface localization, probably due to inefficient intracellular transport by the overloaded sorting machinery of the secretory pathway. Based on our data and the immature glycosylation pattern of FLT3-ITD, we speculate that the mutant protein resides most probably in an unidentified compartment of the secretory pathway between the ER and the Golgi apparatus. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18303245     DOI: 10.1159/000118788

Source DB:  PubMed          Journal:  Cells Tissues Organs        ISSN: 1422-6405            Impact factor:   2.481


  13 in total

Review 1.  Differential signaling of Flt3 activating mutations in acute myeloid leukemia: a working model.

Authors:  Perry M Chan
Journal:  Protein Cell       Date:  2011-02-25       Impact factor: 14.870

2.  Loss of the wild-type allele contributes to myeloid expansion and disease aggressiveness in FLT3/ITD knockin mice.

Authors:  Li Li; Emily Bailey; Sarah Greenblatt; David Huso; Donald Small
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

3.  NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.

Authors:  Rachel Rau; Daniel Magoon; Sarah Greenblatt; Li Li; Colleen Annesley; Amy S Duffield; David Huso; Emily McIntyre; John G Clohessy; Markus Reschke; Pier Paolo Pandolfi; Donald Small; Patrick Brown
Journal:  Exp Hematol       Date:  2013-10-29       Impact factor: 3.084

4.  Impact of CXCR4 inhibition on FLT3-ITD-positive human AML blasts.

Authors:  Angela Jacobi; Sebastian Thieme; Romy Lehmann; Fernando Ugarte; Harry L Malech; Sina Koch; Christian Thiede; Katrin Müller; Martin Bornhäuser; Martin Ryser; Sebastian Brenner
Journal:  Exp Hematol       Date:  2009-12-24       Impact factor: 3.084

Review 5.  The Cytokine Flt3-Ligand in Normal and Malignant Hematopoiesis.

Authors:  Panagiotis Tsapogas; Ciaran James Mooney; Geoffrey Brown; Antonius Rolink
Journal:  Int J Mol Sci       Date:  2017-05-24       Impact factor: 5.923

6.  Dual effects of TGF-beta on ERalpha-mediated estrogenic transcriptional activity in breast cancer.

Authors:  Yongsheng Ren; Liyu Wu; Andra R Frost; William Grizzle; Xu Cao; Mei Wan
Journal:  Mol Cancer       Date:  2009-11-27       Impact factor: 27.401

7.  Modeling pediatric AML FLT3 mutations using CRISPR/Cas12a- mediated gene editing.

Authors:  Natalia Rivera-Torres; Kelly Banas; Eric B Kmiec
Journal:  Leuk Lymphoma       Date:  2020-08-20

Review 8.  Targeted Therapy of FLT3 in Treatment of AML-Current Status and Future Directions.

Authors:  Caroline Benedicte Nitter Engen; Line Wergeland; Jørn Skavland; Bjørn Tore Gjertsen
Journal:  J Clin Med       Date:  2014-12-15       Impact factor: 4.241

9.  Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.

Authors:  K Reiter; H Polzer; C Krupka; A Maiser; B Vick; M Rothenberg-Thurley; K H Metzeler; D Dörfel; H R Salih; G Jung; E Nößner; I Jeremias; W Hiddemann; H Leonhardt; K Spiekermann; M Subklewe; P A Greif
Journal:  Leukemia       Date:  2017-08-14       Impact factor: 11.528

10.  Wild-type FLT3 and FLT3 ITD exhibit similar ligand-induced internalization characteristics.

Authors:  Fabienne Kellner; Andreas Keil; Katrin Schindler; Todor Tschongov; Kerstin Hünninger; Hannah Loercher; Peter Rhein; Sylvia-Annette Böhmer; Frank-D Böhmer; Jörg P Müller
Journal:  J Cell Mol Med       Date:  2020-03-10       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.